LGND - OmniAb initiated with a buy at H.C. Wainwright on antibody collaborations partnerships

• H.C. Wainwright has initiated OmniAb ( NASDAQ: OABI ) with a buy rating saying that the antibody discovery technology company is set to benefit from collaborations and partnerships with other companies.
• The firm has an $11 price target (~184% upside based on Friday's close).
• Analyst Joseph Pantginis calls OmniAb ( OABI ) "an antibody discovery, optimization, and licensing company," adding it has a proprietary platform and a business model that relies on collaborations for revenue.
• OmniAb ( OABI ) itself was spun out from Ligand Pharmaceuticals ( NASDAQ: LGND ) last year .
• OmniAb ( OABI ) has partnerships for candidates in the clinic including Roche's ( OTCQX:RHHBY ) Genentech, Genmab ( GMAB ), Johnson & Johnson's ( JNJ ) Janssen division, Amgen ( AMGN ), and AbbVie ( ABBV ).
• See why Seeking Alpha contributor Out of Ignorance rates OmniAb ( OABI ) a buy.

For further details see: